FDA accepts Belite Bio's tinlarebant NDA for Stargardt Disease Type 1, grants Priority Review with PDUFA target action date February 12, 2027
https://finviz.com/stock?t=BLTE&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.